Navigation Links
Codexis Appoints Interim Chief Executive Officer
Date:2/17/2012

REDWOOD CITY, Calif., Feb. 17, 2012 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that effective immediately, the Board of Directors has appointed Peter Strumph as the company's interim Chief Executive Officer.  Alan Shaw, Ph.D. has resigned as President and Chief Executive Officer and from the Board of Directors to pursue other interests.  He will continue to serve as a special advisor to the Board of Directors.  The Board of Directors has appointed a special committee that will oversee the CEO search and transition.  Heidrick & Struggles has been retained for a worldwide search, which will include both internal and external candidates.

"We are grateful to Alan for his many years of service in leading Codexis from its inception and are pleased that he has agreed to serve as a special advisor to the Board," said Thomas Baruch, Chairman of the Board for Codexis, Inc.  "We are confident that Peter's executive leadership experience and deep understanding of the business will ensure a smooth transition during our search for a permanent CEO."

"Codexis has a tremendous leadership team in place, and I am pleased to continue supporting the company as it works to commercialize industrial enzymes in the biofuel, chemical and pharmaceutical industries," said Dr. Shaw.

Mr. Strumph was the Senior Vice President and Business Head of Pharmaceuticals, where he oversaw a 49% annual increase in pharmaceutical product sales in 2011, as well as the Senior Vice President of Commercial Operations since joining Codexis in 2010.  Mr. Strumph has more than twenty years experience in senior manufacturing and operations management in the biopharmaceutical industry, including executive leadership positions for ten years at CV Therapeutics where he managed their operational, development and commercial activities.  He is a former Naval officer, and holds an MBA from the University of Pennsylvania's Wharton School of Business.   

About Codexis, Inc.

Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, bio-based chemicals and pharmaceutical intermediates.  Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol.  Partners and customers include global leaders such as Shell, Merck and Pfizer.  For more information, see www.codexis.com.

 

Contacts:
Investors: Jay Sarwar, ir@codexis.com, 650-421-8126
Media: Wes Bolsen, media@codexis.com, 650-421-8100


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Announces CFO Departure
2. Codexis to Announce Fourth Quarter and Fiscal Year 2011 Financial Results on February 7, 2012
3. Codexis Reports Third Quarter 2011 Results
4. 50 Pharma Companies Worldwide Now Use Codexis In Process Development
5. Codexis Names Veteran Chemical Executive to Lead Codexis do Brasil
6. Codexis, Raizen to Develop First Generation Ethanol
7. Codexis to Present at Three Investor Conferences in September
8. Codexis Presents Carbon Capture Update at DoE/NETL Conference
9. Codexis Board Elects Pedro I. Mizutani, Raizen EVP, as Director
10. Codexis Reports Second Quarter 2011 Results
11. Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , February 20, 2017 According to a new ... Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, ... by MarketsandMarkets, The market is projected to reach USD 52.37 Billion by ... during the forecast period. Continue Reading ... ...
(Date:2/20/2017)...   Alberty   Drugs , a ... has announced a significant shift in focus by ... to servicing local Veteran Affairs Centers (VA) and other ... increased need to secure cost effective treatments for their ... for their goods & services. "The opportunity ...
(Date:2/20/2017)... , February 20, 2017 Acute, Chronic and ... expected to grow at a CAGR of 7% from 2016-2021 and CAGR ... CAGR of 6% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business opportunities ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... ... to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up ... facilitated by the Pepin Family Foundation. , “We greatly appreciate this gift from ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette ... the Pet Life Radio network. The episode, which was posted this week, features ... what factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... foundational and sustainable systems change designed to further positively impact the health and ... of Trustees has long considered it our duty to seriously consider releasing our ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action ... Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ... action (CA) and preventive action (PA)? , The methods share techniques and tools ...
Breaking Medicine News(10 mins):